LncRNA Information
ID EL0861 Name MEG3 Aliases FP504; GTL2; LINC00023; NCRNA00023; PRO0518; PRO2160; onco-lncRNA-83; prebp1
Species Homo sapiens Chromosome 14 Start site 100779410
End site 100861031 Chain plus Exon NO. 13
Assembly Ensembl Release 89 Class lincRNA NCBI accession NR_046467, NR_046465, NR_046472, NR_046471, NR_033359, NR_003530, NR_033358, NR_002766, NR_046470, N
Ensembl ENSG00000214548 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
pancreatic cancer genome-wide LncRNA microarray analysis pancreatic cancer cell lines down-regulated N/A overexpression of MEG3 induced cells death and increased p53 expression 26850851
non-functioning pituitary adenoma inducible and constitutively active expression systems PDFS cells derived from a human NFA (non-functioning pituitary adenomas) up-regulated expression MEG3 expression significantly suppressed xenograft tumor growth in vivo in nude mice. When induced in culture, MEG3 caused cell cycle arrest at the G1 phase. 26284494
multiple myeloma knockdown, overexpression, ChIP, RIP bone marrow mesenchymal stromal cells (MSCs) down-regulated expression Our data provided novel evidence for the biological and clinical significance of lncRNA MEG3 expression as a potential biomarker for identifying patients with MM and as a potential therapeutic target in MM. 25753650
hepatocellular carcinoma methylation specific PCR (MSP), qRT-PCR, RNA pulldown and western blot analysis, MTT assay, fluorescence microscopy and flow cytometry, improved MS2 biotin tagged RNA affinity purification method hepatoma HepG2 and Huh7 cells up-regulated interaction Ectopic expression of MEG3 inhibited hepatoma cell growth in a time-dependent manner, resulted in cell cycle arrest and induced apoptosis. Adenosine increases MEG3 expression by inhibition of DNA methylation and its antitumor effects is involved in MEG3 activation. 26647875
tongue squamous cell carcinoma microarray, MSP, Western blot, knockdown etc. TSCC tissue, cell lines (SCC-15, CAL27 etc.) down-regulated N/A We report here that miR-26a and lncRNA MEG3 gene expression were both strongly reduced in TSCC compared with levels in matched nonmalignant tissues, and combined low expression levels of both miR-26a and MEG3 emerged as an independent prognostic factor for poor clinical outcome in TSCC patients. 24343426 Lnc2Cancer
hepatocelluar carcinoma microarray, qPCR etc. HCC tissue down-regulated expression Enforced expression of MEG3 in HCC cells significantly decreased both anchorage-dependent and -independent cell growth, and induced apoptosis. Methylation-dependent tissue-specific regulation of the lncRNA MEG3 by miR-29a may contribute to HCC growth. 21625215 LncRNADisease Lnc2Cancer
non-functioning pituitary adenoma microarray, qPCR etc. NFPA tissue down-regulated N/A qPCR analyses showed that MEG3 expression was lost in 32 of 52 NFPAs (61.5 %). In addition, MEG3 lncRNA levels were significantly decreased in invasive NFPAs and non-invasive NFPAs compared to normal anterior pituitaries. Furthermore, MEG3 expression was significantly decreased in invasive NFPAs compared to non-invasive NFPAs. 24469926 LncRNADisease Lnc2Cancer
papillary thyroid carcinoma microarray, qPCR etc. papillary thyroid carcinoma tissue down-regulated interaction Expression profiles of five lnc-RNAs (MEG3, HULC, HOTAIR, NEAT1, and MALAT-1) previously shown to be involved in cancer metastasis were detected by qPCR in 5 pairs of papillary thyroid cancer and 11 matched lymph node metastatic tissues. Among the five, MEG3 showed significant down-expression. Overexpression of MEG3 inhibits thyroid cancer cell migration and invasion.Thus, this study suggests that MEG3 acts as novel suppressor of migration and invasion by targeting Rac1 gene. 25997963 Lnc2Cancer
lung adenocarcinoma microarray, qPCR, Western blot etc. lung cancer tissue, cell lines (A549 etc.) down-regulated interaction MEG3 expression was markedly decreased in cisplatin-resistant A549/DDP cells compared with parental A549 cells as shown by an lncRNA microarray. MEG3 overexpression in A549/DDP cells increased their chemosensitivity to cisplatin both in vitro and in vivo by inhibiting cell proliferation and inducing apoptosis. Moreover, MEG3 was decreased in cisplatin-insensitive LAD tissues while p53 protein levels were decreased and Bcl-xl protein levels increased. 25992654 Lnc2Cancer
prostate cancer microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) down-regulated N/A Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. 23728290 Lnc2Cancer
acute myeloid leukemia MSP etc. bone marrow down-regulated epigenetics MEG3 hypermethylation occurred in 15 MDS patients (34.9%), and in 20 AML patients (47.6%). 19595458 LncRNADisease Lnc2Cancer
glioma N/A gliomas tissues down-regulated epigenetics The downregulation of MEG3 expression due to hypermethylation of MEG3 was observed in gliomas tissues. Treatment of glioma cells with the DNA methylation inhibitor 5-Aza-2'-deoxycytidine (5-AzadC) decreased aberrant hypermethylation of the MEG3 promoter and prevented the loss of MEG3 expression. 26676363
hepatocelluar carcinoma N/A MS2 virus-like particles (VLPs) crosslinked with GE11 polypeptide N/A N/A N/A 26992211
myelodysplastic syndrome N/A N/A N/A epigenetics MEG3 hypermethylation occurred in 15 MDS patients (34.9%), and in 20 AML patients (47.6%). 19595458 LncRNADisease Lnc2Cancer
type 1 diabetes mellitus N/A N/A N/A locus The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. 19966805 LncRNADisease
heroin abuse N/A N/A N/A mutation Intriguingly a genome-wide association study has implicated MEG3 in the vulnerability to heroin addiction. 21128942 LncRNADisease
cancer N/A N/A N/A N/A MEG3 could represent a tumor suppressor gene located in chromosome 14q32 and its association with tumorigenesis is growing every day. 21400503 LncRNADisease
cancer N/A N/A N/A N/A MEG3 functions as a novel lncRNA tumor suppressor. 22393162 LncRNADisease
meningioma N/A N/A N/A regulation MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. 23307326 LncRNADisease
Huntington's disease N/A N/A N/A expression LncRNAs TUG1 (necessary for retinal development), and NEAT-1 (a structural component of nuclear paraspeckles) are upregulated in HD caudate, while the brain-specific tumor-suppressor MEG3 is downregulated in HD. 23346095 LncRNADisease
bladder cancer N/A N/A N/A expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs 24006935 LncRNADisease
hepatocelluar carcinoma N/A N/A N/A expression Braconi et al. found that the expression of maternally expressed gene 3 (MEG3) is markedly reduced in four human HCC cell lines compared with normal hepatocytes and enforced expression of MEG3 in HCC cells significantly induce apoptosis. 24296588 LncRNADisease
bladder cancer N/A N/A N/A regulation Tumour suppressor 24373479 LncRNADisease
kidney cancer N/A N/A N/A expression Tumour suppressor 24373479 LncRNADisease
hepatocelluar carcinoma N/A N/A N/A regulation Expression of MEG3 in tumor cells results in growth suppression, p53 protein increase, and activation of p53 downstream targets. 24757675 LncRNADisease
pituitary adenoma N/A N/A N/A expression Another potential angiogenic lncRNA, Maternally expressed gene 3 (MEG3) was found to be silenced in pituitary adenomas.? 24829860 LncRNADisease
pancreatic neuroendocrine tumors overexpression, microarray pancreatic neuroendocrine tumors (PNETs) cells N/A epigenetics The epigenetic activation of lncRNA MEG3 and/or inactivation of c-MET could be therapeutic for treating PNETs and insulinomas. 25565142
non-functioning pituitary adenoma qPCR etc. pituitary tumor tissue down-regulated epigenetics Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. 15644399 LncRNADisease Lnc2Cancer
phaeochromocytoma qPCR etc. phaeochromocytoma tissue down-regulated N/A Hypermethylation of the GTL2 promoter DMR was detected in 25% of neuroblastomas, 10% of phaeochromocytoma and 2.5% of Wilms' tumours. Tumours with GTL2 promoter DMR hypermethylation also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element. 15798773 LncRNADisease Lnc2Cancer
Wilms' tumor qPCR etc. Wilms' tumor tissue down-regulated N/A Hypermethylation of the GTL2 promoter DMR was detected in 25% of neuroblastomas, 10% of phaeochromocytoma and 2.5% of Wilms' tumours. Tumours with GTL2 promoter DMR hypermethylation also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element. 15798773 LncRNADisease Lnc2Cancer
neuroblastoma qPCR etc. neuroblastoma tissue down-regulated epigenetics MEG3-DMR is completely methylated in neuroblastoma cell lines. 15798773 LncRNADisease Lnc2Cancer
non-functioning pituitary adenoma qPCR etc. pituitary tumor tissue down-regulated expression Maternally Expressed Gene 3 (MEG3), which is specifically associated with clinically non-functioning pituitary adenomas of a gonadotroph lineage. 20211686 LncRNADisease Lnc2Cancer
pituitary adenoma qPCR etc. pituitary tumor tissue down-regulated N/A In summary, MEG3 and GADD45γ expression was significantly lost in most clinically non-functioning adenomas (78 and 92%, respetcively). Other assessed pituitary tumor phenotypes expressed both genes at significantly different levels, and, in some cases, with overexpression. 21850407 Lnc2Cancer
non-functioning pituitary adenoma qPCR etc. pituitary adenoma tissue down-regulated expression The DLK1-MEG3 locus is silenced in NFAs (nonfunctioning adenomas). The DLK1-MEG3 locus plays a tumor suppressor role in human NFAs. 21871428 LncRNADisease Lnc2Cancer
cervical cancer qPCR etc. cell line (CaSki) up-regulated N/A Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. 22487937 LncRNADisease Lnc2Cancer
oral squamous cell carcinoma qPCR etc. OSCC tissues down-regulated N/A We found that most of the selected transcripts (4/6) were upregulated in tumors relative to matched adjacent nonmalignant tissue. One gene, MEG-3, was downregulated in cancer compared with its adjacent nonmalignant tissue. Expression of lncRNA (HOTAIR, NEAT-1 and UCA1) was significantly higher in the samples that subsequently metastasized compared with the non-metastatic samples. By contrast, MEG-3 was downregulated in the metastatic samples. These findings suggest that the detection of lncRNAs in saliva may be used as a noninvasive and rapid diagnostic tool for the diagnosis of oral cancer. 23292713 Lnc2Cancer
pituitary adenoma qPCR etc. pituitary adenomas tissue up-regulated N/A MEG3 lncRNA levels gradually decreased whereas HOTAIR lncRNA levels gradually increased from normal anterior pituitaries to non-invasive NFPAs to invasive NFPAs. There was a significant association between MEG3 (P < 0.01) and HOTAIR (P < 0.05) expression and the biological behavior of the tumor. Furthermore, PCNA mRNA levels markedly increased in invasive NFPAs compared to non-invasive ones (P < 0.01). In addition, PCNA mRNA negatively correlated with MEG3 lncRNA levels 24469926 LncRNADisease Lnc2Cancer
glioma qPCR etc. cell lines(U251, U87) up-regulated expression MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. 25645334 Lnc2Cancer
cervical cancer qPCR, ISH etc. cervical cancer tissue down-regulated N/A A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. 14602737 LncRNADisease Lnc2Cancer
pituitary adenoma qPCR, ISH etc. pituitary tumor tissue down-regulated N/A Therefore, RT-PCR was used to detect specific MEG3a isoform expression in different human pituitary tumor phenotypes. Figure 4B shows that there was no MEG3a expression in three GH-secreting tumors and eight clinically nonfunctioning pituitary tumors, in contrast to the five normal human pituitaries. 14602737 LncRNADisease Lnc2Cancer
prostate cancer qPCR, ISH etc. prostate cancer tissue down-regulated N/A MEG3 mRNA is expressed in the normal human fibroblast cells but is undetectable in human cancer cell lines by Northern blot. Lanes 110, Human carcinoma cells HeLa, MCF-7, T47-D, T24, 5637, Du145, K562, HT29, H1299, H4; lanes 11 and 12, human normal fibroblasts HS-27 and WI38. 14602737 LncRNADisease Lnc2Cancer
breast cancer qPCR, ISH etc. bladder cancer tissue down-regulated expression MEG3 expression is lost. 14602737 LncRNADisease Lnc2Cancer
bladder cancer qPCR, ISH etc. breast cancer tissue down-regulated expression MEG3 expression is lost. 14602737 LncRNADisease Lnc2Cancer
colon cancer qPCR, ISH etc. colon cancer tissue down-regulated expression MEG3 expression is lost. 14602737 LncRNADisease Lnc2Cancer
glioma qPCR, ISH etc. neuroglioma tissue down-regulated expression MEG3 expression is lost. 14602737 LncRNADisease Lnc2Cancer
lung cancer qPCR, ISH etc. lung cancer tissue down-regulated expression MEG3 expression is lost. 14602737 LncRNADisease Lnc2Cancer
chronic myeloid leukemia qPCR, ISH etc. blood down-regulated expression MEG3 expression is lost. 14602737 LncRNADisease Lnc2Cancer
non-functioning pituitary adenoma qPCR, ISH etc. pituitary tumor tissue down-regulated epigenetics Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. 18628527 LncRNADisease Lnc2Cancer
glioma qPCR, Luciferase reporter assay etc. cell lines (U251, U87 etc.) down-regulated expression Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. 22234798 LncRNADisease Lnc2Cancer
meningioma qPCR, Luciferase reporter assay, ISH etc. meningioma tissue down-regulated epigenetics Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. 20179190 LncRNADisease Lnc2Cancer
gastric cancer qPCR, Luciferase reporter assay, RNA pull-down assay etc. gastric cancer tissue, cell lines (MGC-803, HGC-27, MKN-45, SGC-7901, BGC-823, AGS) down-regulated interaction MEG3 is decreased in GC patients and cell lines, and its expression was associated with metastatic GC. Furthermore, ectopic expression of MEG3 in HGC-27 and MGC-803 cells inhibited cell proliferation, migration, invasion, and promoted cell apoptosis, which might be due to MEG3 sequestering oncogenic miR-181 s in GC cells. Furthermore, MEG3 could up-regulated Bcl-2 via its competing endogenous RNA (ceRNA) activity on miR-181a. 26253106 Lnc2Cancer
epithelial ovarian cancer qPCR, MSP, Western blot, Luciferase reporter assay etc. epithelial ovarian cancer tissue, cell lines (OVCAR3, SKOV3, HP8910, ES-2) down-regulated N/A In contrast to normal ovarian tissues, the expression of MEG3 was absent or decreased in most EOC tissues as well as in human EOC cell lines, and the promoter of the MEG3 gene was highly methylated in both cancer tissues and cell lines. In addition, ectopic expression of MEG3 suppressed the proliferation and growth of OVCAR3 cells and promoted apoptosis. Finally, MEG3 activated p53 in OVCAR3 cells. 24859196 Lnc2Cancer
bladder cancer qPCR, Western blot etc. bladder cancer tissue, cell line (T24) down-regulated regulation Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. 23295831 LncRNADisease Lnc2Cancer
non-small cell lung cancer qPCR, Western blot etc. NSCLC tissue, cell lines (A549, SPC-A1,NCI-H1650, NCI-H358, NCI-H1299, NCI-H1975 etc.) down-regulated N/A MEG3 is significantly down-regulated in NSCLC tissues that could be affected by DNA methylation. Overexpression of MEG3 decreased NSCLC cells proliferation and induced apoptosis.Partially via the activition of p53. Thus, MEG3 may represent a new marker of poor prognosis and is a potential therapeutic target for NSCLC intervention. 24098911 Lnc2Cancer
gastric cancer qPCR, Western blot etc. gastric cancer tissue, cell line (GES-1) down-regulated interaction We found that expression of both miR-141 and MEG3 was significantly reduced in GC compared with levels in matched nonmalignant tissues. Positive correlation between miR-141 and MEG3 was found in both tumor tissues and control tissues. Furthermore, the over-expression of either miR-141 or MEG3 in 7901 and MKN45 cells inhibited cell proliferation and cell cycle progression and promoted cell apoptosis. E2F3 was identified as a target of miR-141, and its inhibition significantly reduced MEG3 expression. E2F3 over-expression partly reversed the changes caused by transfection of miR-141 mimic, and inhibition of miR-141 or MEG3 overrides MEG3- or miR-141-induced modulation of cell growth in GC. 26233544 Lnc2Cancer
colorectal cancer qPCR, Western blot, FCA etc. CRC tissue down-regulated expression The lower expression of MEG3 was remarkably correlated with low histological grade, deep tumor invasion, and advanced tumor node metastasis (TNM) stage. Multivariate analyses revealed that MEG3 expression served as an independent predictor for overall survival. Further experiments revealed that overexpressed MEG3 significantly inhibited CRC cell proliferation both in vitro and in vivo. MEG3 is involved in the development and progression of colorectal cancer by regulating cell proliferation and shows that MEG3 may be a potential diagnostic and prognostic target in patients with colorectal cancer. 25636452 Lnc2Cancer
clear cell renal cell carcinoma qPCR, Western blot, FCA etc. ccRCC tissue, cell lines (786-0, SN1) down-regulated interaction The results showed that MEG3 was downregulated in RCC tissues and RCC cell lines. Overexpression of MEG3 could reduce the expression of Bcl-2 and procaspase-9 proteins, enhance the expression of cleaved caspase-9 protein, and promote the release of cytochrome c protein to cytoplasm. Additionally, Bcl-2 mRNA level was declined by MEG3 overexpression. It was concluded that MEG3 induces the apoptosis of RCC cells possibly by activating the mitochondrial pathway. 26223924 Lnc2Cancer
gastric cancer qPCR, Western blot, knockdown etc. gastric cancer tissue, cell lines (SGC-7901, BGC-823, GES-1 etc.) down-regulated N/A We examined the expression of MEG3 in 52 gastric cancer samples using quantitative qPCR and found the down-regulation of MEG3 in both gastric cancer tissues and cell lines. The positive correlation of MEG3 and miR-148a was further confirmed in SGC-7901 and BGC-823 gastric cancer cell lines. Hypermethylation of MEG3 differentially methylated regions was identified by methylation-specific PCR, and MEG3 expression was increased with the inhibition of methylation with siRNA to DNMT-1 in gastric cancer cells. In addition, transfection of MEG3 siRNA into gastric cancer cells diminished the suppression of proliferation induced by overexpression of miR-148a. 24515776 Lnc2Cancer
cervical cancer qPCR, Western blot, knockdown etc. cervical cancer, cell lines (HeLa, CaSki) down-regulated interaction We observed that MEG3 was downregulated in cervical cancer tissues, compared to the adjacent normal tissues, and was negatively related with FIGO stages, tumor size, lymphatic metastasis, HR-HPV infection and the expression of homo sapiens microRNA-21 (miR-21). Furthermore, we focused on the function and molecular mechanism of MEG3, finding that overexpression of MEG3 reduced the level of miR-21-5p expression, causing inhibition of proliferation and increased apoptosis in cervical cancer cells. In summary, our findings indicate that MEG3 function as a tumor suppressor by regulating miR-21-5p, resulting in the inhibition of tumor growth in cervical cancer. 26574780 Lnc2Cancer
prostate cancer qPCR, Western blot, knockdown, Flow cytometry assay etc. prostate cancer tissue, cell lines (PC3, Du145) down-regulated interaction MEG3 decreased significantly in prostate cancer tissues relative to adjacent normal tissues. MEG3 inhibited intrinsic cell survival pathway in vitro and in vivo by reducing the protein expression of Bcl-2, enhancing Bax and activating caspase 3. We further demonstrated that MEG3 inhibited the expression of cell cycle regulatory protein Cyclin D1 and induced cell cycle arrest in G0/G1 phase. 26610246 Lnc2Cancer
cervical cancer qPCR, Western bolt etc. cervical cancer tissue, cell lines (HeLa, C-33A, HCC94 etc.) down-regulated N/A qPCR results showed high expression levels of MEG3 in non-neoplastic tissues, but markedly lower levels in cancer tissues. Ectopic expression of MEG3 inhibited the proliferation of human cervical carcinoma cells HeLa and C-33A in vitro. On the other hand, knockdown of MEG3 promoted the growth of well-differentiated cervical carcinoma HCC94 cells. Further investigation into the mechanisms responsible for the growth inhibitory effects revealed that overexpression of MEG3 resulted in the induction of G2/M cell cycle arrest and apoptosis. 23790166 Lnc2Cancer
gastric cancer qPCR, Western bolt, knockdown etc. gastric cancer tissue, cell lines (SGC7901, AGS, MGC803, MKN45, BGC823 etc.) down-regulated expression Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. 24006224 LncRNADisease Lnc2Cancer
osteosarcoma quantitative real-time PCR (qRT-PCR) osteosarcoma tissues down-regulated expression The expression of lncRNA MEG3 was associated with clinical stage and istant metastasis (P<0.05). Kaplan-Meier analysis showed that patients with low lncRNA MEG3 expression had a shorter overall survival (log-rank test, P<0.05). Furthermore, multivariate analysis revealed that decreased expression of lncRNA MEG3, advanced clinical stage and distant metastasis were all independent predictors to overall survival of osteosarcoma patients. Downregulation of lncRNA MEG3 was associated with poor overall survival of osteosarcoma. LncRNA MEG3 could be a useful biomarker for progression and prognosis of osteosarcoma. 26823857
type 2 diabetes mellitus real-time PCR, western blotting High-fat diet mice, ob/ob mice and mice primary hepatocytes up-regulated interaction MEG3 interference could reverse the up-regulation of triglyceride as well as impaired glucose tolerance and down-regulation of glucogen content in high-fat diet mice or ob/ob mice. Upregulation of lncRNA MEG3 enhances hepatic insulin resistance via increasing foxO1 expression, suggesting that MEG3 may be a potential target and therapeutic strategy for diabetes. 26603935
osteoarthritis RT-PCR articular cartilage samples from 20 Osteoarthritis (OA) patients down-regulated expression Maternally expressed gene 3 (MEG3) is a maternally expressed lncRNA and may function as a tumor suppressor by inhibiting angiogenesis. The results show that human MEG3 is significantly downregulated in OA patients compared to normal cartilage samples. MEG3 may be involved in OA development through the regulation of angiogenesis。 26090403
 


Function (not disease relevant)
Methods Sample/condition Expression pattern Dysfunction type Description PMID Source
RT-qPCR macrophages N/A interaction Knockdown of MEG3 in macrophages resulted in induction of autophagy and enhanced eradication of intracellular M. bovis BCG. 26757825
The luciferase reporter assay and RIP assay EPCs of subjects with MetS up-regulated N/A Pioglitazone up-regulated MEG3 expression to protect EPCs via decreasing miR-140-5p expression and increasing HDAC7 expression in MetS 26898430
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
cAMP DNA-TF regulation Deletion and mutation analysis suggest that a cAMP response element (CRE), located between -69 and -49 of the MEG3 proximal promoter region, is critical for promoter activity. Furthermore, gel shifting, ChIP analysis, and co-transfection experiments show that CREB directly binds to the CRE site and stimulates MEG3 promoter activity. Therefore, MEG3 is a downstream target gene of cAMP. 16793321 LncRNADisease
GDF15 RNA-DNA regulation We further found that MEG3 stimulates expression of the growth differentiation factor 15 (GDF15) by enhancing p53 binding to the GDF15 gene promoter. 17569660 LncRNADisease
p53 RNA-Protein binding We further found that MEG3 stimulates expression of the growth differentiation factor 15 (GDF15) by enhancing p53 binding to the GDF15 gene promoter. 17569660 LncRNADisease
p53 RNA-RNA co-expression MEG3 functions to suppress tumor cell growth, increase protein expression of the tumor suppressor p53, and selectively activate p53 target genes. 20211686 LncRNADisease
p53 RNA-Protein regulation The lncRNA MEG3 is a positive regulator of p53. 20951849 LncRNADisease
Tp53 RNA-DNA regulation The lncRNA MEG3 activates the expression of Tp53 and enhances its binding affinity to the promoter of its target gene. 21247874 LncRNADisease
p53 RNA-DNA regulation Putative tumour suppressor. Regulates p53 expression. Inhibits cell proliferation in the absence of p53. 21256239 LncRNADisease
cAMP response element-binding protein DNA-Protein binding We show that menin activates the long noncoding RNA maternally expressed gene 3 (Meg3) by histone-H3 lysine-4 trimethylation and CpG hypomethylation at the Meg3 promoter CRE site, to allow binding of the transcription factor cAMP response element-binding protein. 25565142
osterix, osteocalcin, BMP4 RNA-Protein regulation We observed that MEG3 knockdown significantly reduced the expression of key osteogenic markers, including Runt-related transcription factor 2, osterix, and osteocalcin, while overexpression of MEG3 enhanced their expression. Additionally, MEG3 knockdown decreased BMP4 transcription. Here we showed that MEG3 was critical for SOX2 transcriptional repression of the BMP4. 25753650
p53 and Bcl-xl RNA-DNA co-expression MEG3 is significantly downregulated in LAD and partially regulates the cisplatin resistance of LAD cells through the control of p53 and Bcl-xl expression. Thus, MEG3 may represent a new marker of poor response to cisplatin and could be a potential therapeutic target for LAD chemotherapy 25992654
Rac1 RNA-DNA regulation we also showed that Rac1 was negatively regulated by lncRNA-MEG3 at the posttranscriptional level, via a specific target site within the 3΄UTR by dual luciferase reporter assay. The expression of Rac1 was inversely correlated with lncRNA-MEG3 expression in PTC tissues. Thus, this study suggests that MEG3 acts as novel suppressor of migration and invasion by targeting Rac1 gene. 25997963
Bcl-2 RNA-RNA regulation Bcl-2 mRNA level was declined by MEG3 overexpression. 26223924
MiR-141 RNA-RNA regulation Mir-141 inhibits gastric cancer proliferation by interacting with long noncoding RNA meg3 and down-regulating e2f3 expression. 26233544
Bcl-2 RNA-Protein regulation MEG3 could up-regulated Bcl-2 via its competing endogenous RNA (ceRNA) activity on miR-181a. 26253106
miR-181 s RNA-RNA regulation MEG3 sequestering oncogenic miR-181 s in GC cells. 26253106
p53 RNA-Protein regulation In addition, inactivation of p53 completely abolished tumor suppression by MEG3, indicating that MEG3 tumor suppression is mediated by p53. 26284494
miR-21 RNA-RNA regulation Overexpression of MEG3 reduced the level of miR-21-5p expression. 26574780
FoxO1, G6pc, Pepck RNA-DNA regulation MEG3 overexpression significantly increased FoxO1, G6pc, Pepck mRNA expressions and hepatic gluconeogenesis and suppressed insulin-stimulated glycogen synthesis in primary hepatocytes, whereas palmitate-induced increase of FoxO1, G6pc and Pepck protein expressions could be reversed by MEG3 interference. 26603935
Bcl-2, Bax, activating caspase 3, Cyclin D1 RNA-Protein regulation MEG3 inhibited intrinsic cell survival pathway in vitro and in vivo by reducing the protein expression of Bcl-2, enhancing Bax and activating caspase 3. MEG3 inhibited the expression of cell cycle regulatory protein Cyclin D1 and induced cell cycle arrest in G0/G1 phase. 26610246
p53, caspase-3, MDM2 and cyclin D1, RNA-Protein regulation Ectopic expression of MEG3 increased p53, caspase-3 mRNA and protein levels, decreased MDM2 and cyclin D1 mRNA and protein levels, as well as ILF3 protein expression in HepG2 cells. 26647875
ILF3 RNA-Protein regulation ILF3 may participate in the anticancer regulation of MEG3 by interacting with MEG3. 26647875
DNMT1 DNA-Protein regulation DNMT1 was involved in MEG3 promoter methylation, and was inversely correlated with MEG3 expression in gliomas. DNMT1-mediated MEG3 hypermethylation caused the loss of MEG3 expression, followed by the inhibition of the p53 pathways in gliomas. 26676363
IFN-γ DNA-Protein regulation IFN-γ induced autophagy in infected macrophages resulted in sustained MEG3 down regulation and lack of IFN-γ allowed for counter regulation of MEG3 by viable M. bovis BCG. 26757825
miR-140-5p RNA-RNA regulation Pioglitazone up-regulated MEG3 expression to protect EPCs via decreasing miR-140-5p expression and increasing HDAC7 expression in MetS 26898430